In pediatric patients (2‑18 years) with moderate‑to‑severe acute asthma exacerbations not responding to repeated short‑acting β‑agonists and systemic corticosteroids, when and how should intravenous magnesium sulfate be administered, including dose, monitoring, and contraindications?

Magnesium in Asthma Exacerbation in Pediatrics

Direct Recommendation

Intravenous magnesium sulfate should be administered at 25-75 mg/kg (maximum 2 g) over 20 minutes in pediatric patients aged 2-18 years with moderate-to-severe acute asthma exacerbations that remain severe after 1 hour of intensive conventional treatment with repeated short-acting β-agonists and systemic corticosteroids. 1

---

When to Administer IV Magnesium Sulfate

Timing Criteria

• After 1 hour of intensive conventional therapy (repeated nebulized albuterol and systemic corticosteroids) with inadequate response 1
• Life-threatening exacerbations presenting with:
  • Too breathless to talk or feed
  • Respirations >50 breaths/min
  • Pulse >140 beats/min
  • PEF <33% predicted or best
  • Silent chest, cyanosis, fatigue/exhaustion
  • Altered mental status or reduced consciousness 2

Clinical Context

The NAEPP Expert Panel Report 3 guidelines explicitly state that IV magnesium sulfate has no apparent value in patients with exacerbations of lower severity but should be considered (conditional recommendation) in those with life-threatening exacerbations and those whose exacerbations remain severe after 1 hour of intensive conventional treatment 1. This selective use has already been adopted by many academic emergency departments.

---

Dosing Protocol

Standard Dose

• 25-75 mg/kg (maximum 2 g) administered intravenously over 20 minutes 1, 3
• The FDA label specifies for adults: 2 g over 20 minutes; for children: 25-75 mg/kg up to maximum 2 g 4

Alternative Continuous Infusion

• Recent research supports 50 mg/kg/h over 4 hours as a continuous infusion, which proved well-tolerated and led to improved respiratory status 5

Preparation

• Must be diluted to a concentration of 20% or less prior to IV infusion 4
• Common diluents: 5% Dextrose or 0.9% Sodium Chloride 4
• Rate of administration should generally not exceed 150 mg/minute 4

---

Monitoring Requirements

Before Administration

• Confirm adequate renal function - magnesium is removed solely by the kidneys 4
• Assess patellar reflex (knee jerk) - must be present 4
• Verify respiratory rate ≥16 breaths/min 4
• Baseline vital signs including blood pressure 4

During and After Infusion

• Continuous monitoring for:
  • Patellar reflexes before each dose (if reflexes absent, hold additional magnesium until they return) 4
  • Respiratory rate (watch for depression <16 breaths/min) 4
  • Blood pressure (hypotension is uncommon but possible) 6
  • Flushing and sweating 4

Target Serum Levels

• Therapeutic range: 3-6 mg/100 mL (2.5-5 mEq/L) to control symptoms 4
• Recent pharmacokinetic data suggests a total serum magnesium AUC₀₋₂ₕ >63.1 mg·h/L correlates with effective dosing 6
• Deep tendon reflexes diminish at levels >4 mEq/L 4
• Reflexes may be absent at 10 mEq/L, where respiratory paralysis becomes a hazard 4

---

Expected Clinical Effects

Efficacy Outcomes

• Moderate improvement in pulmonary function when combined with nebulized β-agonists and corticosteroids 3
• Reduced hospital admissions, particularly in patients with most severe exacerbations 3
• Early and significant improvement in:
  • Peak expiratory flow rate (PEFR)
  • Oxygen saturation (SaO₂)
  • Clinical asthma scores 7
• Improvements typically seen at 30 minutes, 1,2,3, and 7 hours after infusion 7
• Significant improvements in peripheral capillary oxygen saturation (p < 0.001) 8
• Reduced tachypnea in acute asthma exacerbations 8

Mechanism

Magnesium causes relaxation of bronchial smooth muscle independent of serum magnesium level 3

---

Safety Profile

Common Side Effects

• Minor effects only: flushing, light-headedness 3
• Hypotension is uncommon - occurred in only 2/31 IVMg-treated participants in one prospective study with no concentration dependence 6
• No serious treatment-related adverse events reported across multiple studies 8, 9

Contraindications

• Renal impairment/failure (relative contraindication - use with extreme caution) 4, 10
• Atrioventricular block 10
• Absence of patellar reflexes 4
• Respiratory depression (rate <16 breaths/min) 4

Drug Interactions

• CNS depressants (barbiturates, narcotics, hypnotics, anesthetics): adjust dosage due to additive CNS depression 4
• Neuromuscular blocking agents: excessive neuromuscular block may occur 4
• Cardiac glycosides (digoxin): administer with extreme caution - serious cardiac conduction changes and heart block may occur 4
• Calcium: antagonizes CNS depression and peripheral transmission defects produced by magnesium 4

---

Antidote and Overdose Management

Immediate Reversal

• Injectable calcium salt should be immediately available to counteract potential magnesium intoxication 4
• Calcium antagonizes the effects of magnesium overdose 4

Signs of Magnesium Toxicity

• Loss of patellar reflexes
• Respiratory depression or paralysis
• Hypotension
• Altered mental status

---

Clinical Pitfalls to Avoid

1. Do not use in mild-moderate exacerbations - no benefit demonstrated 1
2. Do not delay administration beyond 1 hour of failed conventional therapy in severe cases 1
3. Do not administer undiluted 50% solution IV - must dilute to ≤20% concentration 4
4. Do not exceed infusion rate of 150 mg/minute except in severe eclampsia with seizures 4
5. Do not give if patellar reflexes are absent 4
6. Do not use in patients with significant renal impairment without careful monitoring 4
7. Ensure urine output ≥100 mL in the 4 hours preceding each dose 4

---

Integration with Standard Therapy

Conventional Treatment Must Include

• High-flow oxygen via face mask
• Nebulized albuterol 0.15 mg/kg (minimum 2.5 mg) every 20 minutes for 3 doses 1
• Ipratropium bromide 0.25-0.5 mg nebulized every 20 minutes for 3 doses 1
• Systemic corticosteroids (prednisolone 1-2 mg/kg/day, maximum 40-60 mg) 1, 2

Magnesium as Adjunct

IV magnesium sulfate is used in addition to, not instead of, standard therapy when response is inadequate 3. It represents a bridge therapy to prevent intubation and ICU admission in severe, refractory cases 10.

---

Special Populations

Age Considerations

• Minimum age: 2 years (based on guideline recommendations) 2
• Maximum age: 18 years for pediatric dosing
• Dosing is weight-based (25-75 mg/kg) with absolute maximum of 2 g 1, 4

Renal Impairment

• Use with extreme caution
• Monitor serum magnesium levels closely
• Ensure adequate urine output (≥100 mL/4 hours) 4